The China Food and Drug Administration approved Tagrisso for the treatment of EGFR T790M mutation-positive, locally-advanced or metastatic non-small cell lung cancer in adults whose disease progressed following first-line EGFR tyrosine kinase inhibitor therapy.

Patients are treated with Tagrisso only if they are diagnosed with EGFR T790M mutation in the tumor. The third-generation, irreversible EGFR inhibitor, is now available in more than 45 countries.

Tagrisso is also being investigated for treatment of adjuvant and metastatic first-line settings patients, with and without brain metastases, as well as for the treatment of leptomeningeal disease and in combination therapies.